Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Diletta Favero
Observed names:
D Favero,
D. Favero
Institution:
Candiolo Cancer Institute
Observed institutions:
Ospedale Policlinico San Martino,
Candiolo Cancer Institute,
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer,
University of Genoa
ORCID:
0000-0001-6192-2840
Observed ORCID:
0000-0001-6192-2840
OpenAlex ID:
A5030238156
Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis
2022
·
L Arecco
, E Blondeaux
, et al.
·
Human Reproduction
·
122
PDF
Adverse events and impact on quality of life of antibody‐drug conjugates in the treatment of metastatic breast cancer: A systematic review and meta‐analysis
2025
·
Marta Perachino
, Eva Blondeaux
, et al.
·
European Journal of Clinical Investigation
·
21
PDF
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments
2023
·
Carmine Valenza
, Dario Trapani
, et al.
·
European Journal of Cancer
·
19
Patterns of care at the end of life: a retrospective study of Italian patients with advanced breast cancer
2024
·
Irene Giannubilo
, Linda Battistuzzi
, et al.
·
BMC Palliative Care
·
9
Beyond the Prognostic Value of 2-[18F]FDG PET/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management
2022
·
Roberto Borea
, Diletta Favero
, et al.
·
Diagnostics
·
9
PDF
Hyperthyroidism in non-seminomatous testicular germ cell tumors: two case reports and literature review
2024
·
Diletta Favero
, Christoph Oing
, et al.
·
Frontiers in Oncology
·
3
PDF
Abstract GS3-02: Fertility and ovarian function preservation in premenopausal women with early breast cancer: results from the multicenter prospective PREgnancy and FERtility (PREFER) study
2026
·
M. Lambertini
, E. Blondeaux
, et al.
·
Clinical Cancer Research
·
2
Choosing the appropriate pharmacotherapy for breast cancer during pregnancy: what needs to be considered?
2023
·
Diletta Favero
, Laura Sabina Lapuchesky
, et al.
·
Expert Opinion on Pharmacotherapy
·
2
Practices and views about palliative care at the end of life: A survey of oncologists from the Italian region of Liguria
2024
·
Irene Giannubilo
, Linda Battistuzzi
, et al.
·
Tumori Journal
·
1
290P Adverse events (AEs) and impact on quality of life (QoL) of antibody-drug conjugates (ADC) in the treatment of metastatic breast cancer (mBC): A systematic review and meta-analysis of randomized controlled trials (RCTs)
2024
·
M. Perachino
, E. Blondeaux
, et al.
·
ESMO Open
·
1
PDF
125P Suboptimal ovarian suppression during adjuvant endocrine therapy for premenopausal women with breast cancer: An exploratory analysis of the PREFER and GIM 23 studies
2024
·
S. Nardin
, L. Del Mastro
, et al.
·
ESMO Open
·
1
108P Safety results of post-neoadjuvant T-DM1 in the Italian compassionate use program (GIM26-TRASTHER study)
2023
·
F. Poggio
, M. Tagliamento
, et al.
·
ESMO Open
·
1
PDF
Tubular carcinoma and low-grade hormone receptor-positive breast cancer as candidates for treatment de-escalation
2026
·
Rosa Pennisi
, Diletta Favero
, et al.
·
npj Breast Cancer
PDF
Genomic and clinical characterization of estrogen receptor–positive/HER2-negative early breast cancer: Results from the NextGIM study.
2026
·
Chiara Molinelli
, Barbara Cardinali
, et al.
·
Journal of Clinical Oncology
PDF
Abstract P2-09-18: Comparison of Suboptimal vs. Adequate Ovarian Suppression during Adjuvant Endocrine Therapy for Premenopausal Women with Breast Cancer: An Exploratory Analysis of the PREFER and GIM 23 Studies
2025
·
Simone Nardin
, Edoardo Chiappe
, et al.
·
Clinical Cancer Research
Impact of young age at diagnosis on survival outcomes in patients with early breast cancer according to tumor subtype: Pooled analysis of 5 randomized clinical trials from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM).
2024
·
Marta Perachino
, Eva Blondeaux
, et al.
·
Journal of Clinical Oncology
PDF
Editorial: Diagnostic, prognostic and predictive factors of response in the era of precision oncology in breast cancer
2023
·
Diletta Favero
, Daniele Generali
, et al.
·
Frontiers in Oncology
PDF
66P Outcome predictors for pembrolizumab alone or with chemotherapy in advanced non-small cell lung cancer (NSCLC)
2023
·
L. Zullo
, E. Cella
, et al.
·
Journal of Thoracic Oncology
PDF
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review
2022
·
Francesca Parisi
, Giovanni Rossi
, et al.
·
Precision Cancer Medicine
1043P Clinical predictors of benefit from pembrolizumab (pembro) or pembro-chemotherapy (CHT) in advanced non-small cell lung cancer (NSCLC)
2022
·
L. Zullo
, E. Cella
, et al.
·
Annals of Oncology
PDF
P-463 Anti-Müllerian hormone levels in breast cancer patients receiving chemotherapy with or without concurrent luteinizing hormone-releasing hormone agonist: results from the PROMISE phase III trial
2022
·
C Marrocco
, B Conte
, et al.
·
Human Reproduction
PDF
Assessing the impact of covid-19 outbreak on the attitudes and practice of italian oncologists towards breast cancer care and related research activities
2020
·
Francesca Poggio
, Marco Tagliamento
, et al.
·
Tumori
Gallstone Disease in the Elderly
1999
·
Di Mario
, D. Favero
, et al.
Show more works
View as search
Works count:
23
Citation count:
191
H-index:
5
I10-index:
3
Year
Topic
Type